JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Home
Search results for: 'research area jak stat signaling egfr'

Search results for: 'research area jak stat signaling egfr'

A8219 Gefitinib (ZD1839)

3 Citation

Target: EGFR

Summary: Selective EGFR inhibitor

≥22.34 mg/mL
A3012 Ruxolitinib (INCB018424)

4 Citation

Target: JAK

Summary: JAK inhibitor

insoluble in H2O; ≥15.32 mg/mL
A3018 Trametinib (GSK1120212)

7 Citation

Target: MEK

Summary: MEK1 and MEK2 inhibitor, potent and selective

insoluble in H2O; insoluble in EtOH; ≥15.38 mg/mL
A3433 Gefitinib hydrochloride

Target: EGFR

Summary: Potent EGFR inhibitor

insoluble in EtOH; ≥4.28 mg/mL
A8617 CCT128930 HCl

Target: Akt

Summary: AKT inhibitor

insoluble in H2O; ≥17.1 mg/mL
A1670 Enzastaurin (LY317615)

2 Citation

Target: PKC

Summary: PKC beta inhibitor,potent and selective

insoluble in EtOH; insoluble in H2O; ≥8.59 mg/mL
B2283 Niclosamide

Target: STAT

Summary: Inhibitor of the STAT3 signaling pathway
A3003 MDV3100 (Enzalutamide)

12 Citation

Target: Androgen Receptors

Summary: Androgen receptor antagonist

≥23.22 mg/mL
A4056 AT13387

Target: HSP90

Summary: Hsp90 inhibitor

insoluble in H2O; ≥13.25 mg/mL
A8325 Tivantinib (ARQ 197)

2 Citation

Target: MET

Summary: C-Met inhibitor,non-ATP-competitive

≥18.47 mg/mL